Financial Ratios

PERK PHARMACEUTICALS LTD.

NSE : NABSE : 530673ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE1.980 (0 %)
PREV CLOSE ( ) 1.98
OPEN PRICE ( ) 1.98
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )1.98 1.98
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
Select year
ParticularsMar2014Mar2013Mar2012Mar2011Mar2010
Operational & Financial Ratios
   Earnings Per Share (Rs)0.110.160.140.120.52
   CEPS(Rs)0.300.360.350.340.74
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)6.716.606.446.306.18
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)15.9221.1419.0719.6038.35
   EBIT Margin(%)8.2311.098.558.6727.61
   Pre Tax Margin(%)6.889.937.525.7924.65
   PAT Margin (%)6.889.937.525.7924.65
   Cash Profit Margin (%)18.9422.2719.3316.7335.39
Performance Ratios
   ROA(%)1.151.641.261.095.17
   ROE(%)1.642.492.131.888.69
   ROCE(%)1.912.722.392.719.01
   Asset Turnover(x)0.170.170.170.190.21
   Sales/Fixed Asset(x)0.330.240.240.320.26
   Working Capital/Sales(x)0.330.360.440.730.71
Efficiency Ratios
   Fixed Capital/Sales(x)3.064.184.233.143.77
   Receivable days456.49185.160.00511.89347.30
   Inventory Days158.57171.89177.25181.05188.20
   Payable days0.2772.62353.13523.04302.60
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.000.000.00
   Price/Book(x)0.000.000.000.000.00
   Yield(%)
   EV/Net Sales(x)6.025.845.315.024.99
   EV/Core EBITDA(x)29.6824.9326.0724.0312.89
   EV/EBIT(x)73.2152.6862.0854.3417.91
   EV/CE(x)1.001.020.920.860.98
   M Cap / Sales0.000.000.000.000.00
Growth Ratio
   Net Sales Growth(%)-2.81-9.30-5.12-8.10-3.16
   Core EBITDA Growth(%)-15.884.43-7.52-50.46141.08
   EBIT Growth(%)-27.9417.70-12.18-69.57501.36
   PAT Growth(%)-32.6719.7315.59-77.221227.51
   EPS Growth(%)-32.6719.7315.59-77.221227.51
Financial Stability Ratios
   Total Debt/Equity(x)0.030.020.020.010.07
   Current Ratio(x)46.3875.904.352.263.22
   Quick Ratio(x)40.3963.563.691.832.42
   Interest Cover(x)6.109.508.303.019.33
   Total Debt/Mcap(x)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.